The findings of a systematic review  highlighted the apparent benefits of using a novel intranasal cryotherapy device (ClariFix) for chronic rhinitis that is refractory to medical treatment. Researchers sought to assess the efficacy and safety (adverse outcomes) of ClariFix use. For the study, PRISMA guidelines were followed.

Web of Science, Cochrane, Ovid Medline, Pubmed, and Ovid EMBASE were among the databases that were searched. Studies examining ClariFix use in people with chronic rhinitis of all ages, including allergic and non-allergic rhinitis, fulfilled the inclusion criteria. In the initial search, 1110 studies were detected. The final assessment incorporated eight articles that assessed 472 patients in total.

On the basis of verified outcome measures, the findings illustrated a significant decline in scores after treatment across all studies. All studies' outcome ratings considerably improved from their starting points at all time intervals. The treatment was found to be safe with only minor side effects witnessed by patients such as headache, numbness in the palate, and post-procedural pain and discomfort. There were no serious adverse effects reported.

Hence, cryoablation-based device remarkably improves Total Nasal Symptom Score (TNSS)/reflective TNSS (rTNSS) and presents a viable interventional option to relieve chronic rhinitis.